Talis Biomedical Corp Stock Performance
| TLIS Stock | USD 2.84 0.00 0.00% |
Talis Biomedical holds a performance score of 9 on a scale of zero to a hundred. The entity has a beta of -1.27, which indicates a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Talis Biomedical are expected to decrease by larger amounts. On the other hand, during market turmoil, Talis Biomedical is expected to outperform it. Use Talis Biomedical Corp information ratio and rate of daily change , to analyze future returns on Talis Biomedical Corp.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Talis Biomedical Corp are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unsteady forward indicators, Talis Biomedical unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Talis |
Talis Biomedical Relative Risk vs. Return Landscape
If you would invest 160.00 in Talis Biomedical Corp on November 17, 2025 and sell it today you would earn a total of 124.00 from holding Talis Biomedical Corp or generate 77.5% return on investment over 90 days. Talis Biomedical Corp is currently generating 1.2109% in daily expected returns and assumes 9.6875% risk (volatility on return distribution) over the 90 days horizon. In different words, 87% of pink sheets are less volatile than Talis, and 76% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Talis Biomedical Target Price Odds to finish over Current Price
The tendency of Talis Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 2.84 | 90 days | 2.84 | about 22.05 |
Based on a normal probability distribution, the odds of Talis Biomedical to move above the current price in 90 days from now is about 22.05 (This Talis Biomedical Corp probability density function shows the probability of Talis Pink Sheet to fall within a particular range of prices over 90 days) .
Talis Biomedical Price Density |
| Price |
Predictive Modules for Talis Biomedical
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Talis Biomedical Corp. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Talis Biomedical Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Talis Biomedical is not an exception. The market had few large corrections towards the Talis Biomedical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Talis Biomedical Corp, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Talis Biomedical within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.24 | |
β | Beta against Dow Jones | -1.27 | |
σ | Overall volatility | 0.61 | |
Ir | Information ratio | 0.12 |
Talis Biomedical Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Talis Biomedical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Talis Biomedical Corp can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Talis Biomedical is way too risky over 90 days horizon | |
| Talis Biomedical appears to be risky and price may revert if volatility continues | |
| Talis Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
| Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
Talis Biomedical Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Talis Pink Sheet often depends not only on the future outlook of the current and potential Talis Biomedical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Talis Biomedical's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.8 M | |
| Cash And Short Term Investments | 76.7 M |
Talis Biomedical Fundamentals Growth
Talis Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Talis Biomedical, and Talis Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Talis Pink Sheet performance.
| Return On Equity | -0.7 | |||
| Return On Asset | -0.3 | |||
| Operating Margin | (113.60) % | |||
| Current Valuation | (38.24 M) | |||
| Shares Outstanding | 1.82 M | |||
| Price To Book | 0.06 X | |||
| Price To Sales | 19.57 X | |||
| Revenue | 412 K | |||
| EBITDA | (60.7 M) | |||
| Cash And Equivalents | 165.37 M | |||
| Cash Per Share | 6.21 X | |||
| Total Debt | 19.67 M | |||
| Debt To Equity | 0.19 % | |||
| Book Value Per Share | 26.68 X | |||
| Cash Flow From Operations | (53.24 M) | |||
| Earnings Per Share | (28.02) X | |||
| Total Asset | 98.34 M | |||
| Retained Earnings | (539.96 M) | |||
About Talis Biomedical Performance
Assessing Talis Biomedical's fundamental ratios provides investors with valuable insights into Talis Biomedical's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Talis Biomedical is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Talis Biomedical Corporation operates as a molecular diagnostic company. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California. Talis Biomedical operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 242 people.Things to note about Talis Biomedical Corp performance evaluation
Checking the ongoing alerts about Talis Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Talis Biomedical Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Talis Biomedical is way too risky over 90 days horizon | |
| Talis Biomedical appears to be risky and price may revert if volatility continues | |
| Talis Biomedical has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 412 K. Net Loss for the year was (62.01 M) with loss before overhead, payroll, taxes, and interest of (149.4 M). | |
| Talis Biomedical Corp currently holds about 165.37 M in cash with (53.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.21, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Talis Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Talis Biomedical's stock is overvalued or undervalued compared to its peers.
- Examining Talis Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Talis Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Talis Biomedical's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Talis Biomedical's pink sheet. These opinions can provide insight into Talis Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Talis Pink Sheet Analysis
When running Talis Biomedical's price analysis, check to measure Talis Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Talis Biomedical is operating at the current time. Most of Talis Biomedical's value examination focuses on studying past and present price action to predict the probability of Talis Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Talis Biomedical's price. Additionally, you may evaluate how the addition of Talis Biomedical to your portfolios can decrease your overall portfolio volatility.